Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Vorico vs Vfend in Healthy Volunteers
NCT02631954Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2015
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of voriconazole in aspergillosis, candidiasis and fungal infection (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to the last measurable concentration. Started Sep 2015; status: completed.
02
Drugs
voriconazole
03
Conditions
aspergillosiscandidiasisfungal infection
Beyond the preview
Go deeper on NCT02631954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631954.